Study of newer medications finds 16 percent receive too much or too little
Your search for apixaban returned 71 results
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
For acute major bleeding within 18 hours after factor Xa inhibitor administration, a bolus and infusion of andexanet alfa (andexanet) reduces factor Xa activity, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress.
The FDA has issued a Complete Response Letter (CRL) to the Biologics License Application (BLA) of AndexXa (andexanet alfa; Portola) as a reversal agent for life-threatening or uncontrolled bleeding due to Factor Xa inhibitors.
For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.
The American College of Chest Physicians has released the latest evidence-based guideline with updated recommendations for appropriate treatment of patients with venous thromboembolism (VTE).
Portola Pharmaceuticals announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for its investigational agent andexanet alfa, as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergency surgery. There is currently no…